Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial

Johan Hansson; Steinar Aamdal; Lars Bastholt; Yvonne Brandberg; Micaela Hernberg; Bo Ruby Nilsson; Ulrika Stierner; Hans von der Maase; Nordic Melanoma Cooperative Group

doi:10.1016/S1470-2045(10)70288-6

Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial

Johan Hansson, Steinar Aamdal, Lars Bastholt, Yvonne Brandberg, Micaela Hernberg, Bo Ruby Nilsson, Ulrika Stierner, Hans von der Maase, Nordic Melanoma Cooperative Group

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

85 Citationer (Scopus)

Abstract

Adjuvant high-dose interferon alfa-2b improves relapse-free survival (RFS) in patients with high-risk melanoma, although benefits in overall survival are uncertain. Because of the toxic effects of high-dose regimens, intermediate doses are being explored. We investigated whether adjuvant therapy with intermediate-dose interferon alfa-2b for 1 or 2 years would improve outcomes in patients with stage IIB-IIC or III resected cutaneous melanoma.

Originalsprog	Engelsk
Tidsskrift	Lancet Oncology
Vol/bind	12
Udgave nummer	2
Sider (fra-til)	144-52
Antal sider	9
ISSN	1470-2045
DOI	https://doi.org/10.1016/S1470-2045(10)70288-6
Status	Udgivet - feb. 2011

Adgang til dokumentet

10.1016/S1470-2045(10)70288-6

Biblioteksadgang?

Tjek tilgængelighed hos det Kgl. Bibliotek

Citationsformater

Hansson, J., Aamdal, S., Bastholt, L., Brandberg, Y., Hernberg, M., Nilsson, B. R., Stierner, U., von der Maase, H., & Nordic Melanoma Cooperative Group (2011). Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncology, 12(2), 144-52. https://doi.org/10.1016/S1470-2045(10)70288-6

Hansson, J, Aamdal, S, Bastholt, L, Brandberg, Y, Hernberg, M, Nilsson, BR, Stierner, U, von der Maase, H & Nordic Melanoma Cooperative Group 2011, 'Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial', Lancet Oncology, bind 12, nr. 2, s. 144-52. https://doi.org/10.1016/S1470-2045(10)70288-6

@article{08fca9ab54a549e486f33322b2ab203b,

title = "Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial",

abstract = "Adjuvant high-dose interferon alfa-2b improves relapse-free survival (RFS) in patients with high-risk melanoma, although benefits in overall survival are uncertain. Because of the toxic effects of high-dose regimens, intermediate doses are being explored. We investigated whether adjuvant therapy with intermediate-dose interferon alfa-2b for 1 or 2 years would improve outcomes in patients with stage IIB-IIC or III resected cutaneous melanoma.",

author = "Johan Hansson and Steinar Aamdal and Lars Bastholt and Yvonne Brandberg and Micaela Hernberg and Nilsson, {Bo Ruby} and Ulrika Stierner and {von der Maase}, Hans and {von der Maase}, {Hans Rene Rostgaard}",

year = "2011",

month = feb,

doi = "10.1016/S1470-2045(10)70288-6",

language = "English",

volume = "12",

pages = "144--52",

journal = "Lancet Oncology",

issn = "1470-2045",

publisher = "TheLancet Publishing Group",

number = "2",

}

TY - JOUR

T1 - Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial

AU - Hansson, Johan

AU - Aamdal, Steinar

AU - Bastholt, Lars

AU - Brandberg, Yvonne

AU - Hernberg, Micaela

AU - Nilsson, Bo Ruby

AU - Stierner, Ulrika

AU - von der Maase, Hans

AU - Nordic Melanoma Cooperative Group

PY - 2011/2

Y1 - 2011/2

N2 - Adjuvant high-dose interferon alfa-2b improves relapse-free survival (RFS) in patients with high-risk melanoma, although benefits in overall survival are uncertain. Because of the toxic effects of high-dose regimens, intermediate doses are being explored. We investigated whether adjuvant therapy with intermediate-dose interferon alfa-2b for 1 or 2 years would improve outcomes in patients with stage IIB-IIC or III resected cutaneous melanoma.

AB - Adjuvant high-dose interferon alfa-2b improves relapse-free survival (RFS) in patients with high-risk melanoma, although benefits in overall survival are uncertain. Because of the toxic effects of high-dose regimens, intermediate doses are being explored. We investigated whether adjuvant therapy with intermediate-dose interferon alfa-2b for 1 or 2 years would improve outcomes in patients with stage IIB-IIC or III resected cutaneous melanoma.

U2 - 10.1016/S1470-2045(10)70288-6

DO - 10.1016/S1470-2045(10)70288-6

M3 - Journal article

SN - 1470-2045

VL - 12

SP - 144

EP - 152

JO - Lancet Oncology

JF - Lancet Oncology

IS - 2

ER -